DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Acquired resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) is a significant clinical challenge in treating lung adenocarcinoma (LUAD).
• Understanding the molecular mechanisms underlying EGFR TKI resistance is crucial for developing effective therapeutic strategies.

Purpose of the Study:

• To elucidate the role of dopamine and cyclic AMP-regulated phosphoprotein, Mr 32000 (DARPP-32) in mediating acquired resistance to EGFR TKIs in LUAD.
• To investigate the interaction between DARPP-32, EGFR, and ERBB3 (HER3) in the context of EGFR TKI resistance.

Main Methods:

• Analysis of paired LUAD patient-derived specimens before and after EGFR TKI treatment.
• In vivo studies using mouse xenograft models with DARPP-32 ablation or overexpression.
• Biochemical assays to assess protein interactions and signaling pathway activation.

Main Results:

• DARPP-32, activated EGFR, and ERBB3 are overexpressed in LUAD specimens with acquired resistance to EGFR TKIs.
• DARPP-32 physically recruits ERBB3 to EGFR, promoting the formation of EGFR:ERBB3 heterodimers and bypassing EGFR TKI inhibition.
• DARPP-32 ablation sensitized gefitinib-resistant xenografts to EGFR TKIs, while its overexpression promoted resistance in sensitive tumors.

Conclusions:

• DARPP-32 plays a critical role in a novel ERBB3-dependent mechanism that enables LUAD cells to evade EGFR TKI-induced apoptosis.
• Targeting DARPP-32 presents a potential therapeutic strategy to overcome acquired resistance and improve treatment outcomes for EGFR TKI-refractory LUAD.